Timothy E Corcoran1, Joseph E Godovchik1, Karl H Donn2, David R Busick2, Jennifer Goralski3, Landon W Locke1, Matthew R Markovetz4, Michael M Myerburg1, Ashok Muthukrishnan5, Lawrence Weber5, Ryan T Lacy1, Joseph M Pilewski1,6,7. 1. Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Parion Sciences, Durham, North Carolina. 3. Pulmonary and Critical Care Medicine, Pediatric Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. 4. Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. Department of Cell Biology, University of Pittsburgh, Pittsburgh, Pennsylvania. 7. Department of Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
AIM: Inhaled hypertonic saline increases mucociliary clearance, improves pulmonary function, and decreases exacerbations in cystic fibrosis (CF) but contributes to the already significant treatment burden of CF. Overnight delivery of inhaled medications via a specially designed nasal cannula-aerosol device (Trans-nasal Pulmonary Aerosol Delivery [tPAD]) is an alternative approach. Here, we test whether overnight inhalation of hypertonic saline via tPAD improves mucociliary clearance and assess the tolerability of the device. METHOD: In this study, 12 CF subjects inhaled 7% hypertonic saline (HS) for 8 h overnight using the tPAD system. Safety and tolerability were assessed and measurements of mucociliary and absorptive clearance (MCC/ABS) were performed after the treatment. Comparisons were made versus sham treatment where the same subjects wore the nasal cannula overnight but did not receive aerosol. RESULTS: Both the HS and sham treatments were well-tolerated. Only one subject did not complete the overnight HS treatment. There were no significant differences in MCC associated with HS inhalation at any time point (90 min, 3 h, 6 h) in any lung zone. Changes in FEV1 on both study days were similar. There were no differences in quality of sleep between HS and sham nights as assessed with the modified Leeds Sleep Evaluation Questionnaire (mLSEQ). Sino-Nasal Outcome Test (SNOT-14) questionnaires demonstrated significant increases (worsening) in 2/14 symptom categories with HS. CONCLUSIONS: The most likely cause for the failure to accelerate MCC was under-dosing of HS relative to the active transport of salt from the airways.
RCT Entities:
AIM: Inhaled hypertonic saline increases mucociliary clearance, improves pulmonary function, and decreases exacerbations in cystic fibrosis (CF) but contributes to the already significant treatment burden of CF. Overnight delivery of inhaled medications via a specially designed nasal cannula-aerosol device (Trans-nasal Pulmonary Aerosol Delivery [tPAD]) is an alternative approach. Here, we test whether overnight inhalation of hypertonic saline via tPAD improves mucociliary clearance and assess the tolerability of the device. METHOD: In this study, 12 CF subjects inhaled 7% hypertonic saline (HS) for 8 h overnight using the tPAD system. Safety and tolerability were assessed and measurements of mucociliary and absorptive clearance (MCC/ABS) were performed after the treatment. Comparisons were made versus sham treatment where the same subjects wore the nasal cannula overnight but did not receive aerosol. RESULTS: Both the HS and sham treatments were well-tolerated. Only one subject did not complete the overnight HS treatment. There were no significant differences in MCC associated with HS inhalation at any time point (90 min, 3 h, 6 h) in any lung zone. Changes in FEV1 on both study days were similar. There were no differences in quality of sleep between HS and sham nights as assessed with the modified Leeds Sleep Evaluation Questionnaire (mLSEQ). Sino-Nasal Outcome Test (SNOT-14) questionnaires demonstrated significant increases (worsening) in 2/14 symptom categories with HS. CONCLUSIONS: The most likely cause for the failure to accelerate MCC was under-dosing of HS relative to the active transport of salt from the airways.
Authors: Scott H Donaldson; William D Bennett; Kirby L Zeman; Michael R Knowles; Robert Tarran; Richard C Boucher Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Landon W Locke; Michael M Myerburg; Matthew R Markovetz; Robert S Parker; Lawrence Weber; Michael R Czachowski; Thomas J Harding; Stefanie L Brown; Joseph A Nero; Joseph M Pilewski; Timothy E Corcoran Journal: Eur Respir J Date: 2014-04-17 Impact factor: 16.671
Authors: Mieke Boon; Stijn E Verleden; Barbara Bosch; Elise J Lammertyn; John E McDonough; Cindy Mai; Johny Verschakelen; Mariette Kemner-van de Corput; Harm A W Tiddens; Marijke Proesmans; François L Vermeulen; Erik K Verbeken; Joel Cooper; Dirk E Van Raemdonck; Marc Decramer; Geert M Verleden; James C Hogg; Lieven J Dupont; Bart M Vanaudenaerde; Kris De Boeck Journal: Am J Respir Crit Care Med Date: 2016-03-01 Impact factor: 21.405
Authors: Timothy E Corcoran; Alex S Huber; Michael M Myerburg; Daniel J Weiner; Landon W Locke; Ryan T Lacy; Lawrence Weber; Michael R Czachowski; Darragh J Johnston; Ashok Muthukrishnan; Alison T Lennox; Joseph M Pilewski Journal: J Aerosol Med Pulm Drug Deliv Date: 2019-04-10 Impact factor: 2.849
Authors: Benjamin M Spence; Worth Longest; Xiangyin Wei; Sneha Dhapare; Michael Hindle Journal: J Aerosol Med Pulm Drug Deliv Date: 2019-03-11 Impact factor: 2.849